|4Mar 31, 7:28 PM ET

Downs Christopher 4

4 · CNS Pharmaceuticals, Inc. · Filed Mar 31, 2023

Insider Transaction Report

Form 4
Period: 2023-03-29
Downs Christopher
Chief Financial Officer
Transactions
  • Award

    Restricted Stock Units

    2023-03-29+6,06728,768 total
    Common stock (6,067 underlying)
Footnotes (3)
  • [F1]Each restricted stock unit represents a contingent right to receive one shares of Issuer common stock.
  • [F2]The restricted stock units set forth in this table vest as follows, subject to the grantee's continued service to the Company on each vesting date, (i) 50% of the grant will vest in four equal annual installments over 4 years; (ii) 25% of the grant will vest if within 24 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $6.00 (subject to pro rata adjustment for stock splits or similar events); and (iii) 25% of the grant will vest if within 36 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $24.00 (subject to pro rata adjustment for stock splits or similar events).
  • [F3]Issued in connection with the reporting person's employment with the Company.

Documents

1 file
  • 4
    ownership.xmlPrimary